Literature DB >> 24508145

Subgroup analysis in randomized controlled trials appeared to be dependent on whether relative or absolute effect measures were used.

Roderick P Venekamp1, Maroeska M Rovers2, Arno W Hoes3, Mirjam J Knol3.   

Abstract

OBJECTIVES: To assess whether relative or absolute effect measures were used in subgroup analyses of randomized controlled trials (RCTs) and study whether conclusions would change if subgroup effects were calculated on a different scale than reported. STUDY DESIGN AND
SETTING: We studied all 327 RCTs published in 2010 in five major medical journals. For trials with a dichotomous primary outcome, we extracted reported main and subgroup effect measures. If crude subgrouping data were reported, we calculated the subgroup effects on both relative and absolute scales.
RESULTS: Of the 229 RCTs with a dichotomous primary outcome, 120 (52%) performed subgroup analyses. In 106 of these 120 (88%) RCTs, relative effect measures were used for subgroup analyses, whereas an absolute scale was used in 9 (8%) trials. Two (2%) RCTs reported both relative and absolute subgroup effects. Crude data of the subgroups could be extracted in 41 of the 120 (34%) RCTs. Calculating subgroup effects on a different scale than reported lead to a change in conclusion in 17% of the 41 trials.
CONCLUSION: Almost all RCTs used relative effect measures for subgroup analyses. Interpretation of subgroup effects, however, appeared to be dependent on whether relative or absolute effect measures were used.
Copyright © 2014 Elsevier Inc. All rights reserved.

Keywords:  Absolute risk reduction; Epidemiology; Randomized controlled trials; Relative risk reduction; Subgroup analysis; Treatment effects

Mesh:

Year:  2014        PMID: 24508145     DOI: 10.1016/j.jclinepi.2013.11.003

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  5 in total

1.  Confounding, effect modification, and the odds ratio: common misinterpretations.

Authors:  Ian Shrier; Menglan Pang
Journal:  J Clin Epidemiol       Date:  2015-01-08       Impact factor: 6.437

2.  Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.

Authors:  Issa J Dahabreh; Rodney Hayward; David M Kent
Journal:  Int J Epidemiol       Date:  2016-12-01       Impact factor: 7.196

Review 3.  The quality of subgroup analyses in chronic pain randomized controlled trials: a methodological review.

Authors:  Mahmood AminiLari; Vahid Ashoorian; Alexa Caldwell; Yasir Rahman; Robby Nieuwlaat; Jason W Busse; Lawrence Mbuagbaw
Journal:  Korean J Pain       Date:  2021-04-01

4.  Quantification of Treatment Effect Modification on Both an Additive and Multiplicative Scale.

Authors:  Nicolas Girerd; Muriel Rabilloud; Philippe Pibarot; Patrick Mathieu; Pascal Roy
Journal:  PLoS One       Date:  2016-04-05       Impact factor: 3.240

Review 5.  Evidence of selective reporting bias in hematology journals: A systematic review.

Authors:  Cole Wayant; Caleb Scheckel; Chandler Hicks; Timothy Nissen; Linda Leduc; Mousumi Som; Matt Vassar
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.